Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, Joshi S, Pimple S, Kawade A, Balasubramani L, Thomas A, Suri V, Lalwani S, Uday R, Kamath V, Mandal R, Rajeswar A, Peedicayil A, Poli UR, Banerjee D, Sankaranarayanan R, Basu P, Muwonge R, Gairola S, Dogar V, Rao H, Shaligram U.
Sharma H, et al.
Lancet Oncol. 2023 Dec;24(12):1321-1333. doi: 10.1016/S1470-2045(23)00480-1. Epub 2023 Nov 7.
Lancet Oncol. 2023.
PMID: 37949086
Clinical Trial.
BACKGROUND: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. ...The availability of the SIIPL quadrivalent HPV vaccine could help meet the global demand for HPV vac …
BACKGROUND: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human pap …